Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: lefamulin, recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Source
No articles found.
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and d...
Cocrystal Pharma, Inc. is a clinical stage biot...
AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) f...
AzurRx BioPharma is a development stage biophar...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Join the National Investor Network and get the latest information with your interests in mind.